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Abbreviations: BMMC, bone marrow-derived cultured mast cell; ES cell, embryonic 
stem cell; FACS, fluorescence activated cell sorting; FcεRI, high affinity receptor for 
IgE; GFP, green fluorescent protein; IgE, immunoglobulin E; IL-3, interleukin-3; LPS, 
lipopolysaccharide; MC, mast cell; OVA, ovalbumin; SCF, stem cell factor; TLR, 
toll-like receptor; TNP, 2, 4, 6-trinitrophenyl. 
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Abstract 
Mast cells (MCs) play pivotal roles in allergic reactions and the host defense 
against microbial infection through the IgE-dependent and IgE-independent signaling 
pathways. MC lines that can be analyzed both in vitro and in vivo would be useful for 
the study of MC-dependent immune responses. Here we investigated the functional 
characteristics of a mouse embryonic stem cell-derived MC-like cell line, 
MEDMC-BRC6. The cell line expressed FcεRI and c-Kit and showed degranulation and 
production of inflammatory cytokines and chemokine, including TNF-a, IL-6 and 
MCP-1, upon crosslinking FcεRI with IgE. These cytokines and chemokine were also 
produced by the cell line by stimulation of TLR2 and TLR4. MEDMC-BRC6 survived 
in the peritoneal cavity and the ear skin for at least 6months after the transfer into 
genetically compatible MC-deficient KitW-sh/W-sh mice, in which systemic anaphylaxis 
was successfully induced. Thus, MEDMC-BRC6 cells represent a potent tool for 
investigating the functions of MCs in vitro and in vivo.  
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Introduction 
Mast cells (MCs) play a central role in IgE-mediated immediate 
hypersensitivity reactions (1,2). MCs are also involved in the adaptive and innate 
immune response against pathogens through TLRs (3). MCs originate from 
hematopoietic stem cells and reside in nearly all vascularized tissues. Previous studies 
on the in vitro analyses of the functions of mouse MCs have mostly been conducted 
using the rat basophilic RBL-2H3 cell line and bone marrow-derived cultured MCs 
(BMMCs). However, RBL-2H3 cells carry a constitutively active form of the c-Kit 
receptor (4), which influences FcεRI-signaling (5). BMMCs have been transferred into 
an MC-deficient mouse for in vivo studies (6). However, BMMCs from genetically 
engineered animals that exhibit an embryonic lethal phenotype are not available. 
Embryonic stem (ES) cells are continuously growing stem cell lines that can be 
utilized for the generation of lineage-committed cells. MCs were also differentiated 
from ES cells in vitro (7-11). This in vitro technique for initiating the differentiation of 
ES cells into ES-derived MC is a powerful system for investigating the functions of 
MCs. It was reported that MCs generated from both wild-type and ES cells that are 
genetically manipulated in vitro can survive and display IgE-dependent passive 
cutaneous anaphylaxis in vivo at 3 weeks after intra-dermal injection into MC-deficient 
KitW/KitW-v mice (9). However, it remains unclear whether ES-derived MCs can be 
Shibagaki et al, International Immunology, 29: 235, 2017 
	
5	
	
stably cultured over long periods in vitro and whether their properties are maintained 
during long-term culturing. 
MEDMC-BRC6 is an established mouse ES-derived MC-like cell line that 
expresses FcεRI and c-Kit and requires exogenous cytokines to survive (12). In the 
present study, we investigated the functional characteristics of MEDMC-BRC6 cells in 
vitro and in vivo. 
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Materials and methods 
Cells and reagents 
The mouse ES-derived MC-like cell lines, MEDMC-BRC6, were purchased 
from RIKEN BioResource Center (BRC, Tsukuba, Japan) and were cultured as 
described previously (12). Briefly, cells were cultured in IMDM (Thermo Fisher 
Scientific, Waltham, MA, USA) containing the following materials: 15% fetal bovine 
serum (Sigma, St Louis, MO, USA); 10 µg/ml bovine insulin, 5.5 µg/ml human 
transferrin, and 5 ng/ml sodium selenite (ITS liquid MEDIA supplement; Sigma); 50 
µg/ml ascorbic acid (Sigma); 0.45 mM Monothioglycerol (Wako, Tokyo, Japan); 100 
unit/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine (PSQ; Sigma). 
Mouse IL-3 (3 ng/ml; R&D Systems, Minneapolis, MN, USA) and mouse stem cell 
factor (SCF, 30 ng/ml; R&D Systems) were used for the culturing of MEDMC-BRC6 
cells. MEDMC-BRC6 cells were frozen and thawed according to RIKEN BRC’s 
instructions. MEDMC-BRC6 cells that stably expressed GFP were generated using a 
retroviral vector, pMXs (a kind gift from Dr. Toshio Kitamura, University of Tokyo), as 
described previously (13). The efficiency of retroviral transduction into MEDMC-BRC6 
cells was ~30%. The GFP+ cells were sorted using a FACSAria cell sorter (BD 
Biosciences, Mountain View, CA, USA). The BMMCs were prepared by culturing bone 
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marrow cells with SCF (10 ng/ml) and IL-3 (4 ng/ml) for 4 weeks as described 
previously (13). The cells were cytocentrifuged at 500 rpm for 5 min (Shandon 
CytoSpin 3), and stained with Wright (Muto Pure Chemicals Co., Ltd., Tokyo, Japan), 
or 1.0% alcian blue at pH 2.5 (Wako) followed by 0.1% safranin O (Sigma). All images 
were acquired using a BZ-X710 microscope (Keyence, Osaka, Japan), and the data were 
analyzed using a BZ-H3 analyzer (Keyence). TLR2/TLR6-binding diacylated 
lipopeptide Pam2CSK4 (InvivoGen, San Diego, CA, USA) and TLR4 ligand LPS 
(Sigma) were used for stimulation of cells.  
 
Quantitative reverse transcription PCR analysis 
 Total RNA was isolated from cell pellets (TRIzol, Thermo Fischer Scientific, 
Waltham, MA, USA) and used as a template for reverse transcription reactions 
(High-Capacity cDNA RT Kit, Applied Biosystems, Foster City, CA, USA). 
Quantitative PCR analysis of mouse MC proteases (MCPs) was performed by using an 
ABI7500 sequence detector (Applied Biosystems) and Power SYBR Green Master Mix 
(Applied Biosystems). The primers were:  
Mmcp-1 (forward,5ʹ-ttcccttgcctggtccct-3ʹ; reverse, 5ʹ-gttttcccccagccagct-3ʹ)  
Mmcp-2 (forward, 5ʹ-cattgcctagttcctctgacttca-3ʹ; reverse, 5ʹ-cctgttttcccccatccag-3ʹ) 
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Mmcp-4 (forward, 5ʹ-cttctgactttatcaagccggg-3ʹ; reverse, 5ʹ-cactccagttcgccccc-3ʹ) 
Mmcp-5 (forward, 5ʹ-ctgcagtggcttcctgataa-3ʹ; reverse, 5ʹ-ggaattgcttttccacctca-3ʹ) 
Mmcp-6 (forward, 5ʹ-gcccagccaatcagcg-3ʹ; reverse, 5ʹ-ccagggccacttactctcaga-3ʹ) 
Mmcp-7 (forward, 5ʹ-catgcagcccccggt-3ʹ; reverse, 5ʹ-ttcccatgtgcctcctgtc-3ʹ) 
Mmcp-8 (forward, 5ʹ-ttcctcgggtattcaccagaa-3ʹ; reverse, 5ʹ-gggttgttgcaggagtttcatt-3ʹ) 
Mmcp-9 (forward, 5ʹ-gggtggcccatggtattgta-3ʹ; reverse, 5ʹ-cgggtgaagattgcaggg-3ʹ) 
Mmc-cpa (forward, 5ʹ-gctacacattcaaactgcctcct-3ʹ; reverse, 5ʹ-gagagagcatccgtggcaa-3ʹ) 
Gapdh (forward, 5ʹ-tggtgaaggtcggtgtgaac-3ʹ; reverse, 5ʹ-atgaaggggtcgttgatggc-3ʹ)  
All experiments were performed in triplicate.  
 
Cytometric bead array analysis 
The concentrations of inflammatory cytokines (TNF and IL-6) and chemokine 
(MCP-1) were measured by a cytometric bead array (CBA) analysis according to the 
manufacturer’s instructions. Briefly, the culture supernatants (10 µl) from stimulated 
cells (4-5 ×105 cells in 100-200 µl) were mixed with 10 µL of mixed captured beads 
from mouse Flex Set Cytometric Bead Array (Becton Dickinson, San Jose, CA, USA, 
Cat. No. 51-9005324, 51-9005236, 51-9005252), then detected with PE detection 
reagents (Becton Dickinson, Cat. No. 51-9004161, 51-9004153, 51-9004296). Flow 
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cytometric analysis was performed using the BD LSR Fortessa cell analyzer (BD 
Biosciences) and CBA analysis FCAP software (Becton Dickinson).  
 
Flow cytometry 
The cells were stained with mAbs as indicated. Cells were treated with 
anti-CD16/32 mAb (2.4G2; TONBO Biosciences, San Diego, CA, USA) to avoid 
binding to FcγR on ice for 10 min prior to incubation with the indicated combination of 
antibodies. Monoclonal antibodies against mouse c-Kit (2B8) and TLR2 (6C2) were 
purchased from BD Biosciences. Anti-mouse TLR4 (SA15-21) and CD11b (M1/70) 
were purchased from BioLegend. Anti-mouse FcεRIα (MAR-1) was purchased from 
eBiosciences. Anti-mouse CD45.2 (104) was purchased from TONBO Biosciences. 
Stained cells were acquired on a BD LSR Fortessa cell analyzer and were analyzed 
using the FlowJo software program (Tree Star, Inc., Ashland, OR, USA). 
 
Degranulation assay 
Degranulation was evaluated by measuring the release of β-hexosaminidase 
and by a flow cytometric analysis of the cell-surface exposure of CD107a (LAMP-1). 
LAMP-1 is an intracellular protein found on granule membranes that becomes exposed 
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on MC surface upon degranulation (14). The cells were sensitized with the indicated 
concentration of IgE anti-2,4,6-trinitrophenyl (anti-TNP, C38-2; BD Biosciences) in 
culture medium for 15 h at 37°C and were then stimulated with the indicated 
concentration of TNP4-conjugated ovalbumin (OVA) in 100 µl HEPES–Tyrode’s buffer 
(pH 7.4) at 37°C. Cells that were stimulated with ionomycin (1 µg/ml; Sigma) for 30 
min were used as a positive control of degranulation. Culture supernatants or cells were 
collected at 30 or 10 minutes after the addition of the antigen, respectively. The culture 
supernatants were analyzed to detect the release of β-hexosaminidase and the percent 
degranulation was calculated as described previously (13). Cells were stained with 
anti-CD107a mAb (1D4B; BD Biosciences) and were analyzed by flow cytometry. 
  
Reconstitution of KitW-sh/W-sh mice with MEDMC-BRC6 cells 
 MC–deficient KitW-sh/W-sh mice on the C57BL/6 background and C57BL/6 mice 
were purchased from RIKEN BRC and Clea Japan, respectively. KitW-sh/W-sh mice were 
reconstituted with 2×107 of GFP-expressing MEDMC-BRC6 cells or 107 of BMMCs by 
intravenous injection. Three to 6 months after the injection, mice were analyzed for 
reconstitution of MC in the peritoneal cavity and ear pinnae by flow cytometry and the 
stomach by histology. Mouse ear pinnae were treated and stained as described 
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previously	 (15,16). Briefly, ears were treated with enzyme mixture containing 
collagenase II and DNase I (400 U/ml and 50 U/ml, respectively; Worthington 
Biochemical, Lakewood, NJ, USA) for 1 h at 37°C with shaking, then stained with 
indicatedmAbs. Peritoneal MCs and ear skin MCs were positive for both FcεRI and 
c-Kit. To analyze tissue MC in the stomach, 3 µm paraffin sections of fixed tissues with 
4% paraformaldehyde were stained with 0.05% toluidine blue O (Chroma-Gesellschaft, 
Schmid & Co., Stuttgart, Germany) or with 1 % alcian blue, pH2.5 (Wako) in 3% acetic 
acid for 30 minutes followed, after washing, by 0.1% safranin O (sigma) for 5 minutes.    
 
Passive systemic anaphylaxis 
KitW-sh/W-sh mice that had been intravenously injected with 2 × 107 cells of 
GFP-expressing MEDMC-BRC6 cells 6 months previously were sensitized with an 
intravenous injection of mouse IgE anti-TNP (20 µg; C38-2; BD Biosciences). 
Twenty-four hours later, the mice were challenged with an intravenous injection of 
TNP6-OVA (1 mg). After the antigen challenge, the rectal temperatures were measured 
every 5 min for 60 min using a digital thermometer (Shibaura Electronics, Tokyo, 
Japan). The mice used in all of the experiments were 8 to 13-week-old males and had 
been bred in the specific pathogen-free facilities at the University of Tsukuba. All 
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animal experiments in this study were carried out humanely, and all efforts were made 
to minimize suffering after receiving approval from the Animal Ethics Committee of the 
Laboratory Animal Resource Center, University of Tsukuba (Permit Number: 16–281), 
and in accordance with Fundamental Guideline for Proper Conduct of Animal 
Experiment and Related Activities in Academic Research Institutions under the 
Jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology.  
 
Statistical analysis 
The results were expressed as mean ± SEM. The values were analyzed by 
parametric ANOVA. P values of <0.05 were considered to indicate statistical 
significance.
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Results and discussion 
The FcεRI-mediated activation of signaling in MEDMC-BRC6 cells 
MEDMC-BRC6 cell was generated by culturing C57BL/6-derived ES cells (BRC6) on 
feeder cells (OP9 cells) with cytokines (SCF, EPO, and IL-3) (12). MEDMC-BRC6 
cells exhibit mast cell (MC)-like phenotypes because they harbor basic granules (Fig. 
1A) and express high-affinity receptor for IgE, FcεRI and c-Kit on their cell surface (Fig. 
1B) (12). However, the number and size of granules in the cytoplasm of 
MEDMC-BRC6 cells were smaller and the expression level of FcεRI and c-Kit was 
lower than those of BMMCs (Fig. 1A), suggesting that MEDMC-BRC6 cells were 
immature compared with BMMCs. Similarly to bone BMMCs, MEDMC-BRC6 cells 
require both IL-3 and SCF for their survival and proliferation (12). However, their 
functions remain unclear. To characterize the phenotype of MEDMC-BRC6 cells, we 
stained MEDMC-BRC6 cells and BMMCs with alcian blue followed by safranin O. 
Mucosal MCs (MMCs) are preferentially stained with alcian blue due to the 
predominance of chondroitin sulphate. In contrast, safranin O rather than alcian blue 
preferentially stains connective tissue MCs (CTMC) due to the predominance of heparin 
(17). While BMMCs were positive for alcian blue, but not safranin O, MEDMC-BRC6 
cells were positive for both alcian blue and safranin O (Fig. 1C), suggesting that 
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MEDMC-BRC6 had both characteristics of MMCs and CTMCs. Classification of 
CTMC and MMC can be determined by the expression of mouse MC secretory granule 
proteases (mMCPs) (18). To further phenotypically characterize MEDMC-BRC6 cells, 
we examined the relative gene expression levels of mMCPs in MEDMC-BRC6 and 
BMMC by quantitative reverse transcription PCR analyses. MEDMC-BRC6 cells 
expressed lower levels of mMCP-1, -2, -4, -5, -6, -7, -8, -9, and MC–carboxypeptidase 
A (MC-CPA) than did BMMCs (Fig. 1D), consistent with the results of morphological 
and phenotypical analyses (Fig. 1A), suggesting again that MEDMC-BRC6 cells were 
immature compared with BMMCs. 
To clarify whether MEDMC-BRC6 cells can transduce signals via FcεRI, the 
cells were sensitized with an anti-TNP IgE antibody and then stimulated with various 
concentrations of TNP-conjugated OVA. Stimulation of MEDMC-BRC6 cells as well as 
BMMCs sensitized with an anti-TNP IgE with the TNP-conjugated OVA antigen 
induced degranulation, as determined by CD107a expression and β-hexosaminidase 
release (Fig. 2A and B). These results indicated that although the degranulation was less 
in MEDMC-BRC6 cells compared with BMMCs, FcεRI mediated an activating signal 
for degranulation in MEDMC-BRC6 cells. Next, we measured the production of 
proinflammatory cytokines and chemokine, including TNF-α, IL-6, and MCP-1 at 24 h 
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after antigen stimulation using a CBA. In accordance with the results of the 
degranulation experiment, MEDMC-BRC6 cells secreted inflammatory cytokines and 
chemokines upon crosslinking FcεRI although the amounts of secreted cytokines and 
chemokines were less in MEDMC-BRC6 cells compared with BMMCs (Fig. 2C). 
Together, these results suggest that although the strength of signal through FcεRI in 
MEDMC-BRC6 cells seemed to be lower than that in BMMCs, MEDMC-BRC6 cells 
can be utilized to investigate the FcεRI-mediated signaling pathway in MCs in vitro. 
 
TLR-mediated signaling in MEDMC-BRC6 cells 
MCs are also activated through TLR-mediated signaling (19) and play an 
important role in the host defense against pathogens (20). Next, we examined the 
expression of TLR2 and TLR4 on MEDMC-BRC6 cells by flow cytometry and found 
that they expressed both TLRs (Fig. 3A and B). The cells were then stimulated with 
TLR2–TLR6-binding diacylated polypeptides, Pam2CSK4 or the TLR4 ligand, LPS. 
MEDMC-BRC6 cells, as well as BMMCs secreted inflammatory cytokines, including 
TNF-α, IL-6, and MCP-1 in response to stimulation with Pam2CSK4 (Fig. 3C) or LPS 
(Fig. 3D). Although, the expression of TLR2 on BMMCs was hardly detected by flow 
cytometry, the production of cytokines was induced in a dose-dependent manner of 
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Pam2CSK4. Nonetheless, these results indicate that MEDMC-BRC6 cells can be used 
to investigate the signaling pathways mediated by TLR2 and TLR4 in MCs in vitro.  
 
MEDMC-BRC6 cells survive in MC-deficient mice 
MEDMC-BRC6 cells are differentiated from mouse ES cells with a C57BL/6 
background and require exogenous IL-3 and SCF for their survival (12). Based on these 
observations, we hypothesized that—similarly to BMMCs—MEDMC-BRC6 cells may 
survive in MC-deficient mice with a C57BL/6 background without exhibiting 
tumorigenicity in vivo. To achieve this, MC-deficient KitW-sh/W-sh mice with a C57BL/6 
background was intravenously injected with 2×107 MEDMC-BRC6 cells, which had 
been retrovirally transduced with GFP. KitW-sh/W-sh mice transplanted with 107 of 
BMMCs were generated as a control. We analyzed the MCs in the peritoneal cavity 
fluid (PEC) and ear skin by flow cytometry and found that in C57BL/6 mice, 1–3% of 
the CD11b- cells in the PEC and 4–7% of the CD45+ CD11b- cells in the ear skin were 
FcεRI+c-Kit+ MCs (Fig. 4A and B). In accordance with previous reports, no 
FcεRI+c-Kit+ cells were detected in the PEC or ear skin of KitW-sh/W-sh mice (Fig. 4A and 
B) (6). However, at 24 weeks after the transfer of MEDMC-BRC6 cells into KitW-sh/W-sh 
mice, we detected FcεRI+c-Kit+ cells in the PEC (Fig. 4A). Similarly to BMMCs, 
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MEDMC-BRC6 cells in the peritoneal cavity of KitW-sh/W-sh mice were detected at 12 
weeks after the transfer. Previous study demonstrated that intravenous injection of 
BMMCs did not result in reconstitution of MC in the ear skin of KitW-sh/W-sh mice (6). 
Consistently, we also did not detect MC in the ear skin of KitW-sh/W-sh mice with 
intravenous injection of BMMC at 12 and 24 weeks after the transfer (data not shown). 
However, at 24 weeks after the transfer of MEDMC-BRC6 cells into KitW-sh/W-sh mice, 
we could detect FcεRI+c-Kit+ cells in the ear skin (Fig. 4B), which might be dependent 
on the characteristic of MEDMC-BRC6 cells with the safranin O-positive phenotype 
that is also observed in CTMC locating primarily in the skin. Therefore, we addressed 
whether MEDMC-BRC6 cells with the characteristic of the safranin O-positive 
phenotype survive in the stomach, where MC shows the MMC phenotype positive for 
alcian blue but negative for safranin O in wild–type mice (Fig 4D). While KitW-sh/W-sh 
mice that received BMMCs intravenously showed the recruitment of MCs positive for 
alcian blue, but not safranin O, into the stomach at 12 weeks after the transfer, MCs 
observed in the stomach of KitW-sh/W-sh mice that received MEDMC-BRC6 cells showed 
the safranin O, but not alcian blue, -positive phenotype (Fig. 4D). This result suggests 
that MCs in the stomach of MEDMC-BRC6-transferred mice exhibit the CTMC-like 
phenotype. No tumors were observed in those mice (data not shown). These results 
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indicate that MEDMC-BRC6 cells can survive for at least 6 months without 
tumorigenicity in vivo. 
 
MEDMC-BRC6 cells compensate for the function of MCs in MC-deficient mice 
Since MEDMC-BRC6 cells were adapted in vivo, we next assessed whether 
MEDMC-BRC6 cells in KitW-sh/W-sh mice could orchestrate typical IgE-dependent and 
MC-dependent passive systemic anaphylaxis.	 KitW-sh/W-sh mice before and 6 months 
after the transfer with GFP-expressing MEDMC-BRC6 cells as well as wild type–mice 
were passively sensitized with IgE antibodies against TNP and then challenged with an 
intravenous injection of TNP-conjugated OVA (TNP-OVA). We measured the rectal 
temperature, an indicator of passive systemic anaphylaxis, every 5 min after the antigen 
challenge. The IgE-sensitized wild–type mice showed a progressive decrease in rectal 
temperature within 20 min after the antigen challenge, whereas the KitW-sh/W-sh mice did 
not show a decrease in rectal temperature (Fig. 4E). This finding was consistent with 
previous observations (13). As we expected, KitW-sh/W-sh mice transferred with 
GFP-expressing MEDMC-BRC6 cells showed a progressive decrease in rectal 
temperature at 24 weeks after the transfer (Fig. 4E). These results indicate that 
MEDMC-BRC6 cells can be utilized for the systemic analysis of the FcεRI-mediated 
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functions of MCs in vivo. 
In the present study, we demonstrated that gene-manipulated MEDMC-BRC6 
cells survive and compensate for the IgE-dependent functions of MCs in MC-deficient 
mice without displaying tumorigenicity. These properties were stable and were observed 
continuously for >1 year after the induction of their differentiation from ES cells. 
Moreover, the doubling time of MEDMC-BRC6 cells was 17 ± 0.2 h, which was 3 to 
5-fold faster than that of BMMCs. The efficiency of retroviral transduction into 
MEDMC-BRC6 cells was ~30%. Thus, large numbers of genetically manipulated MCs 
can be ready for use in a short period, and their physiological role can be investigated 
systemically in vivo. Importantly, intravenous injection of MEDMC-BRC6 cells, but not 
BMMCs, preferentially adapt to the skin. Thus, MEDMC-BRC6 cells may be a useful 
material to investigate the function of MC, particularly in the skin, in vivo as well as in 
vitro.   
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Figure legends 
Fig 1. The phenotypic analyses of MEDMC-BRC6 cells 
Cytospins of MEDMC-BRC6 cells and BMMCs were stained with Wright (A) or with 
alcian blue followed by safranin O (C). (B) Flow cytometric analysis of cell-surface 
expressions for FcεRI and c-Kit. The data are shown as 5% probability contour plots. 
(D) Quantitative reverse transcription PCR analysis of MCPs and CPA. The relative 
gene expression levels were determined in triplicate. GAPDH, glyceraldehyde 
3-phosphate dehydrogenase (used as an internal control for normalization). The figures 
are representative results of two independent experiments.  
 
Fig 2. FcεRI-mediated signaling in MEDMC-BRC6 cells  
(A) MEDMC-BRC6 cells and BMMCs were sensitized with the anti-TNP IgE mAb, 
and then challenged with the indicated concentrations of TNP4-conjugated OVA antigen. 
(A) The cells were stained with mAbs against CD107a and c-Kit at 10 min after antigen 
stimulation and were analyzed by flow cytometry (n = 3). The proportion of CD107a+ 
c-Kit+ cells is shown. (B) The culture supernatants were collected from at 30 min after 
the antigen challenge and β-hexosaminidase activity was determined (n = 3). (C) The 
culture supernatants were collected from (A) at 24 h after antigen challenge, and 
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cytokines and chemokines production was analyzed by CBA (n = 3). The data represent 
the results of three independent experiments (mean ± SD). ** P < 0.01, *** P < 0.001. 
 
Fig 3. TLR-mediated signaling in MEDMC-BRC6 cells  
Flow cytometric analyses of the expression of TLR2 (A) and TLR4 (B) on 
MEDMC-BRC6 cells and BMMCs. The cells were stimulated with Pam2CSK4 (C) or 
LPS (D) for 24 h, and then the culture supernatants were analyzed for cytokine 
production by CBA (n = 3). The data represent the results of three independent 
experiments (mean ± SD). *** P < 0.001. 
 
Fig 4. MEDMC-BRC6 cells survive for 24 weeks and compensate for the function of 
MCs in MC-deficient KitW-sh/W-sh mice  
KitW-sh/W-sh mice were transplanted with 2 ×107 of GFP-expressing MEDMC-BRC6 cells 
or 107 of BMCMs. Flow cytometric analyses of FcεRI+c-Kit+ MCs in the PEC (A) and 
the ear skin (B) were analyzed at 12 or 24 weeks after the transplantation. The numbers 
indicate the proportion of FcεRI+c-Kit+ MCs in CD11b- cells (A) and CD45+ CD11b- 
cells (B). The data are shown as 5% probability contour plots. Tissues from stomachs 
were stained with toluidine blue (C) or with alcian blue followed by safranin O (D) at 
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12 weeks after the transplantation. Original magnification: ×400. Arrowheads indicate 
the MCs (E) The rectal temperatures of C57BL/6 mice (n = 2/group) and KitW-sh/W-sh 
mice transplanted with (MEDMC-BRC6 → KitW-sh/W-sh; n = 3/group) or without 
MEDMC-BRC6 cells (KitW-sh/W-sh mice; n = 3/group). At 24 weeks after the transfer, the 
mice were sensitized with mouse IgE anti-TNP (20 µg), then challenged with 
TNP6-OVA (1 mg). The data represent the results of two independent experiments 
(mean ± SEM). * P < 0.05 as compared with values for KitW-sh/W-sh mice by ANOVA.  
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